Baird lowered the firm’s price target on Karyopharm (KPTI) to $15 from $21 and keeps an Outperform rating on the shares. The firm updated its model following mixed Ph 3 Sentry data which may still have a possible path forward in MF.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm price target lowered to $8 from $15 at H.C. Wainwright
- Karyopharm Announces Financing and Positive SENTRY Trial Results
- Karyopharm up 23% after Phase 3 SENTRY trial meets first co-primary endpoint
- Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint
- Karyopharm announces $30M private placement